Cargando…

Real‐life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52‐week multicentre retrospective study—IL PSO (Italian landscape psoriasis)

BACKGROUND: Tildrakizumab is a humanized monoclonal antibody that binds selectively the p19 subunit of interleukin‐23. It is approved for treatment of moderate–severe chronic plaque psoriasis. OBJECTIVES: We conducted a 52‐week retrospective study to assess the effectiveness and safety of tildrakizu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Narcisi, Alessandra, Valenti, Mario, Gargiulo, Luigi, Ibba, Luciano, Amoruso, Fabrizio, Argenziano, Giuseppe, Bardazzi, Federico, Burlando, Martina, Carrera, Carlo Giovanni, Damiani, Giovanni, Dapavo, Paolo, Dini, Valentina, Franchi, Chiara, Girolomoni, Giampiero, Guarneri, Claudio, Loconsole, Francesco, Sampogna, Francesca, Travaglini, Massimo, Malagoli, Piergiorgio, Costanzo, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles and Short Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092064/ https://www.ncbi.nlm.nih.gov/pubmed/36156312 http://dx.doi.org/10.1111/jdv.18594

Ejemplares similares

Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study—IL PSO (Italian landscape psoriasis)
por: Gargiulo, Luigi, et al.
Publicado: (2023)

Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study—IL PSO (Italian landscape psoriasis)
por: Gargiulo, Luigi, et al.
Publicado: (2023)

Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting
por: Burlando, Martina, et al.
Publicado: (2021)

Erythrodermic psoriasis improved by Tildrakizumab
por: Trevisan, Giampaolo, et al.
Publicado: (2022)

Tildrakizumab in the treatment of psoriasis – literature review
por: Banaszczyk, Katarzyna
Publicado: (2019)

Tildrakizumab in the treatment of psoriasis: latest evidence and place in therapy
por: Pithadia, Deeti J., et al.
Publicado: (2019)

Tildrakizumab: A new therapeutic option for erythrodermic psoriasis?
por: Megna, Matteo, et al.
Publicado: (2021)

Effectiveness and Safety After a Switch to Tildrakizumab: A Real World Multicenter Italian Study in Psoriasis
por: Di Brizzi, Eugenia Veronica, et al.
Publicado: (2023)

Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study
por: BORRONI, Riccardo G., et al.
Publicado: (2021)

Characteristics of Patients Experiencing a Flare of Generalized Pustular Psoriasis: A Multicenter Observational Study
por: Bellinato, Francesco, et al.
Publicado: (2023)

Long term efficacy, safety, and tolerability of tildrakizumab in epileptic patient with psoriasis and eczema
por: Bernardini, Nicoletta, et al.
Publicado: (2022)

Secukinumab in Patients with Psoriasis and a Personal History of Malignancy: A Multicenter Real-Life Observational Study
por: Pellegrini, Cristina, et al.
Publicado: (2022)

Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: A Northern Italy experience
por: Gisondi, Paolo, et al.
Publicado: (2021)

Efficacy of Secukinumab in Psoriasis: Post Hoc Gender-Wise Analysis of the SUPREME Study
por: Stingeni, Luca, et al.
Publicado: (2023)

Sub‐erythrodermic psoriasis successfully treated with bimekizumab: A case report
por: Valenti, Mario, et al.
Publicado: (2022)

The CANOVA Study Real-World Evidence of Biologic Treatments in Moderate-Severe Psoriasis in Italy: A Gender Perspective
por: Colombo, Delia, et al.
Publicado: (2022)

A Case of Concurrent Psoriasis and Hidradenitis Suppurativa Successfully Treated with Tildrakizumab
por: Damsin, Thomas
Publicado: (2023)

Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement
por: Fargnoli, Maria Concetta, et al.
Publicado: (2023)

Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations
por: Gisondi, Paolo, et al.
Publicado: (2021)

Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date
por: Beck, Kristen M, et al.
Publicado: (2018)

Erratum: Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting
Publicado: (2021)

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence
por: Ruggiero, Angelo, et al.
Publicado: (2022)

Patients’ demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasis
por: Scala, Emanuele, et al.
Publicado: (2020)

A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study
por: Zagni, Emanuela, et al.
Publicado: (2021)

Anti-interleukin-17 and anti-interleukin-23 biologic drugs for genital psoriasis: a single-center retrospective comparative study
por: Cortese, Andrea, et al.
Publicado: (2023)

Incidence of serious gastrointestinal events among tildrakizumab‐treated patients with psoriasis: Letter to the Editor
por: Gooderham, M., et al.
Publicado: (2019)

Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis
por: Galluzzo, Marco, et al.
Publicado: (2022)

Tildrakizumab in moderate‐to‐severe plaque psoriasis: A multicenter, retrospective, real‐life study
por: Caldarola, Giacomo, et al.
Publicado: (2022)

Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest
por: Reich, K., et al.
Publicado: (2015)

Tildrakizumab: An Evidence-Based Review of Its Use in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis
por: Näslund-Koch, Charlotte, et al.
Publicado: (2020)

Anti‐interleukin‐23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real‐world practice
por: Ruggiero, A., et al.
Publicado: (2021)

Implementation of the PsoWell™ Model for the Management of People with Complex Psoriasis
por: HEWITT, Rachael M., et al.
Publicado: (2021)

A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab
por: Ghazawi, Feras M., et al.
Publicado: (2021)

Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study
por: Ruggiero, Angelo, et al.
Publicado: (2023)

Efficacy and Safety of Secukinumab in Elderly Patients with Moderate to Severe Plaque-Type Psoriasis: Post-Hoc Analysis of the SUPREME Study
por: Talamonti, Marina, et al.
Publicado: (2023)

Sharing Patient and Clinician Experiences of Moderate-to-Severe Psoriasis: A Nationwide Italian Survey and Expert Opinion to Explore Barriers Impacting upon Patient Wellbeing
por: Prignano, Francesca, et al.
Publicado: (2022)

Dimethyl Fumarate Treatment in Patients with Moderate-to-Severe Psoriasis: A 52-week Real-life Study
por: GNESOTTO, Laura, et al.
Publicado: (2023)

The Budget Impact of Introducing Tildrakizumab to a United States Health Plan for Managing Moderate-to-Severe Plaque Psoriasis
por: Carrico, Justin, et al.
Publicado: (2020)

Clearance of head and neck involvement in plaque psoriasis with tildrakizumab treatment in the phase 3 reSURFACE 1 study
por: Menter, M.A., et al.
Publicado: (2020)

Saliva as a Future Field in Psoriasis Research
por: Asa'ad, Farah, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_eul0j1if1shm52t8l146kjaio4